ArcheMedX, Inc.

ArcheMedX, Inc. is a clinical trial technology company that creates innovative solutions aimed at improving the readiness and efficiency of clinical trials through its specialized training and risk identification platform. ArcheMedX, Inc. focuses on enhancing clinical trial readiness with its technology platform.

Founded by Brian McGowan and Joel Selzer, the company is headquartered in Charlottesville, US. As of October 2017, ArcheMedX raised USD 2. 5 mn in a funding round co-led by investors Jaffray Woodriff and Greyson Williams, marking a pivotal moment in its growth. The company specializes in the development of the Ready platform, which enhances clinical trial readiness and streamlines site activation for study teams.

This platform assists clinical professionals by offering tailored training and risk identification strategies that lead to improved trial performance. The Ready platform is utilized by 21 of the top 25 pharmaceutical firms and has recorded over 1,000,000 user sessions across more than 90 countries, addressing critical use cases related to study startup acceleration, enrollment efficiency, and trial compliance. ArcheMedX provides its products and services in various international markets, including North America, Europe, and emerging markets in Asia and Latin America. ArcheMedX generates revenue primarily through subscription-based models for its Ready platform, catering to clinical research organizations (CROs), trial sponsors, and commercial teams.

The company engages in B2B transactions with tiered pricing plans tailored to the needs of clients such as large pharmaceutical companies and biotechs. Subscriptions encompass access to various platform capabilities, including risk assessment tools and tailored training sessions. Partnerships with healthcare organizations and educational institutions further bolster ArcheMedX’s revenue streams. Looking ahead, ArcheMedX plans to leverage its recent funding of USD 2.

5 mn, raised in October 2017, to enhance its platform capabilities and explore new product offerings. The company aims to expand its reach into new markets, particularly focusing on regions in Asia and Latin America by the end of 2024. The funding will support the continued development of innovative solutions to meet the growing needs of clinical trial stakeholders and improve trial performance globally.